在全球医药产业格局加速重构的背景下,中国西药行业正经历从规模扩张向质量跃升的关键转型。人口老龄化带来的慢性病管理需求激增、医疗技术突破催生的创新药浪潮,以及政策端对创新研发的持续激励,共同推动行业进入高质量发展新阶段。一、西药行业市场发展现状分析(一)技术突破:从“仿制跟随”到“源头创新”中国西药行业的技术创新已突破传统路径依赖,形成多维度突破格局。在肿瘤领域,PD-1/L1抑制剂、EGFR-...
Source Link在全球医药产业格局加速重构的背景下,中国西药行业正经历从规模扩张向质量跃升的关键转型。人口老龄化带来的慢性病管理需求激增、医疗技术突破催生的创新药浪潮,以及政策端对创新研发的持续激励,共同推动行业进入高质量发展新阶段。一、西药行业市场发展现状分析(一)技术突破:从“仿制跟随”到“源头创新”中国西药行业的技术创新已突破传统路径依赖,形成多维度突破格局。在肿瘤领域,PD-1/L1抑制剂、EGFR-...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.